FREE TO ATTEND: eyeforpharma Barcelona Virtual
Covid-19 has created one of the most challenging environments in decades. Ironically, despite the travel restrictions, it’s more important than ever for the pharma industry to share ideas and inspiration. We have therefore decided not to cancel, but to reinvent eyeforpharma Barcelona 2020 as a virtual event, free of charge for all to engage with. Between March 30th and April 3rd, more than 2000 attendees will be able to experience the first online edition of this event.
What to expect from eyeforpharma Barcelona Virtual:
• Over 100 Confirmed Speakers: We’re bringing you the eyeforpharma Barcelona 6 stream agenda to your fingertips. We’re working with all presenters and panellists to ensure that the virtual experience will be as close to the real agenda as possible. With 70+ confirmed sessions already the virtual experience will be unparalleled in scope and expertise.
• Full Audience Interactivity: It’s the interactions that make events special. That’s why we’re ensuring that all presentations, fireside chats, panels and everything else you can think of will have full interactivity capability, including live Q&A and audience polls.
• One-to-one Meeting and Networking Service: Connect with all your fellow attendees and potential new partners through a dedicated virtual meetings platform. You will be able to message, schedule meetings and use a virtual meeting room to ensure even in isolation you are not isolated from new connections, ideas and partnerships.
• The Virtual Exhibition: Search through over 50+ exhibitors from your own desk. Whether you work in clinical or commercial, you’ll be able to find the latest services and technology solutions across the entire product lifecycle.
"Now more than ever, we need to share ideas and collaborate. eyeforpharma's online solution is the answer"
Haider Alleg, Global Head of Digital, Ferring
Our ambition is to ensure we don’t become isolated in our isolation.
eyeforpharma Barcelona Virtual Pass: EUR 0.00
Speakers: Klaus Dugi, EVP, Chief Medical Officer, Ferring, Charlotte Kremer, EVP, Head of Medical Affairs, Astellas, Edward Trott, Chief Patient Officer, Ferring, Chris Round, EVP, Head of International Operations & Global Core Franchises, Merck, John Zibert, CM, LEO Innovation Lab, Kristian, Hart-Hansen CEO, LEO Innovation Lab, Colin Sims, EVP, Strategy, Kyowa Kirin International, Jeffrey Wren, EVP, Neurology Patient Value Head, UCB, Kris Sterken, Company Group Chairman, EMEA , Janssen, Florent Edouard, SVP, Global Head of Commercial Excellence & Customer Engagement, Grünenthal, Christian Scheuer, VP, Global Commercial Affairs & Excellence, LEO Pharma, Michael Seewald, VP, Global Head, Real World Evidence, Novartis, Chris Boone, VP, Global Medical Epidemiology & Big Data Analysis, Pfizer, Ryan Olohan, Managing Director, Healthcare, Google, Steven Hildemann, SVP, Chief Bio-Ethics & Employee Health, Merck, Rodney Smith, VP, Head of Medical Affairs Europe, Daiichi Sankyo, Anish Shindore, VP, Head of Digital Acceleration - DTx, Sanofi, Austin Speier, Chief Strategy Officer, Click Therapeutics, Jacob LaPorte, Co-Founder, Novartis BIOME, Benjamine Liu, CEO, TrialSpark, Andy Powrie-Smith, Executive Director, Communications & Partnerships, EFPIA, Anjan Chatterjee, VP, Real World Evidence - COE, Epidemiology and Big Data, Boehringer Ingelheim, Francesca Wuttke, Chief Digital Officer, Almirall, Philipp Maerz, CEO, Allergopharma, Jeremy Sohn, VP, Global Head of Digital BD&L, Novartis, Pol Vandenbroucke, SVP, Chief Medical Officer, Hospital Business Unit, Pfizer, Nicholas Brooke, Executive Director, Patient Focused Medicine Development, Badhri Srinivasan, Head, Global Development Operations, Novartis, Mads Dalsgaard, Senior Vice President, Head of Experimental Medicine & Clinical Development, Lundbeck, Niko Andre, Head of Global Medical Affairs, Roche, Renaud Sermondade, VP, Global Head of Insights and Analytics, Sanofi, Nicola Bedlington, Special Advisor, European Patients Forum, Bozidar Jovicevic, VP, Global Head of Digital Therapeutics, Sanofi, Martin Price, VP, Health Economics, Market Access and Reimbursement, EMEA, Janssen, Tamir Singer, Head of Commercial Access & Value, Commercial Medicines Directorate, NHS England